Glaukos (NYSE:GKOS - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday, Wall Street Zen reports.
GKOS has been the topic of a number of other research reports. Jefferies Financial Group boosted their target price on shares of Glaukos from $190.00 to $210.00 and gave the stock a "buy" rating in a research note on Tuesday, September 22nd. Citigroup raised their target price on Glaukos from $225.00 to $247.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. UBS Group started coverage on shares of Glaukos in a report on Tuesday, July 28th. They set a "neutral" rating and a $150.00 price target on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a research report on Thursday, October 15th. Finally, Stifel Nicolaus boosted their price target on shares of Glaukos from $190.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $216.71.
View Our Latest Stock Report on GKOS
Glaukos Stock Performance
Glaukos stock opened at $223.96 on Friday. Glaukos has a 52-week low of $80.90 and a 52-week high of $255.18. The company has a fifty day simple moving average of $178.24 and a 200-day simple moving average of $144.09. The company has a quick ratio of 4.09, a current ratio of 4.57 and a debt-to-equity ratio of 0.09.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. The company had revenue of $211.03 million for the quarter, compared to analysts' expectations of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The firm's revenue for the quarter was up 58.0% compared to the same quarter last year. During the same period last year, the company earned ($0.16) EPS. As a group, sell-side analysts predict that Glaukos will post 0.50 EPS for the current year.
Insider Transactions at Glaukos
In related news, COO Joseph E. Gilliam sold 60,000 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer owned 72,588 shares of the company's stock, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert Kliman sold 2,500 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total value of $632,500.00. Following the transaction, the director directly owned 37,406 shares of the company's stock, valued at approximately $9,463,718. The trade was a 6.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 65,000 shares of company stock valued at $11,891,900. 5.90% of the stock is currently owned by company insiders.
Institutional Trading of Glaukos
A number of large investors have recently made changes to their positions in GKOS. BlackRock Inc. purchased a new stake in shares of Glaukos during the second quarter valued at $1,333,318,000. Jupiter Topco LLC purchased a new position in Glaukos in the 2nd quarter valued at approximately $679,614,000. Primecap Management Co. CA purchased a new position in shares of Glaukos during the second quarter valued at about $424,969,000. Janus Henderson Group PLC boosted its position in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier's stock worth $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new position in shares of Glaukos during the 2nd quarter worth about $92,476,000. Institutional investors and hedge funds own 99.04% of the company's stock.
About Glaukos
(
Get Free Report)
Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.
Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.